Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. Sanders made the remark at an expert roundtable event on Capitol Hill, which served as a preview to Novo Nordisk CEO Lars Fruergaard Jørgensen's testifying before the Senate HELP Committee next week. In June, Jørgensen agreed to testify over the pricing of Ozempic in the U.S., as well as that of the drugmaker's hugely popular weight loss drug Wegovy. Novo Nordisk charges around $1,300 a month for Wegovy in the U.S., even though the drug can be purchased for $186 a month in Denmark, $137 in Germany and $92 in the United Kingdom.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
